Lifesci Capital Forecasts Lower Earnings for Kodiak Sciences

Key Points

• Lifesci Capital cut its Q1 2026 EPS estimate for Kodiak to ($0.73) from ($0.64) and lowered near‑term forecasts, joining other analysts in revisions that raise short‑term earnings uncertainty.
• Kodiak reported Q4 EPS of ($1.04), missing estimates by $0.02, but management highlighted pipeline progress (notably Phase III data for Zenkuda), leaving analyst sentiment mixed-to-favorable with a consensus "Moderate Buy" and a $35.43 average price target.
• The stock opened at $40.63 while trading well above its 50‑day ($26.08) and 200‑day ($22.62) moving averages, and is heavily institutionalized (about 89% ownership) after several funds added or increased positions in Q4.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Stock analysts at Lifesci Capital decreased their Q1 2026 earnings estimates for Kodiak Sciences in a research report issued to clients and investors on Wednesday, April 1st. Lifesci Capital analyst P. Dolezal now anticipates that the company will earn ($0.73) per share for the quarter, down from their prior estimate of ($0.64). The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. Lifesci Capital also issued estimates for Kodiak Sciences' Q2 2026 earnings at ($0.74) EPS, Q3 2026 earnings at ($0.77) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($2.52) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Tuesday, March 31st. The company reported ($1.04) earnings per share for the quarter, missing analysts' consensus estimates of ($1.02) by ($0.02).

Several other analysts have also weighed in on the company. Weiss Ratings reissued a "sell (e+)" rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. UBS Group upped their target price on Kodiak Sciences from $50.00 to $80.00 and gave the company a "buy" rating in a research note on Friday, March 27th. Finally, HC Wainwright reiterated a "buy" rating and set a $58.00 price target (up from $38.00) on shares of Kodiak Sciences in a research note on Friday, March 27th. Five research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Kodiak Sciences has an average rating of "Moderate Buy" and a consensus price target of $35.43.

Kodiak Sciences Stock Down 5.1%

Kodiak Sciences stock opened at $40.63 on Friday. The business has a 50 day moving average price of $26.08 and a two-hundred day moving average price of $22.62. The stock has a market cap of $2.51 billion, a price-to-earnings ratio of -9.41 and a beta of 2.39. Kodiak Sciences has a 12 month low of $1.92 and a 12 month high of $45.60.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors have recently added to or reduced their stakes in KOD. T. Rowe Price Investment Management Inc. acquired a new position in shares of Kodiak Sciences in the 4th quarter worth approximately $11,440,000. Invesco Ltd. lifted its position in shares of Kodiak Sciences by 454.1% during the 4th quarter. Invesco Ltd. now owns 555,073 shares of the company's stock worth $15,520,000 after buying an additional 454,894 shares during the period. Ikarian Capital LLC boosted its stake in Kodiak Sciences by 73.9% in the 4th quarter. Ikarian Capital LLC now owns 719,787 shares of the company's stock valued at $20,125,000 after buying an additional 305,946 shares in the last quarter. Virtus Investment Advisers LLC bought a new stake in Kodiak Sciences in the fourth quarter valued at $312,000. Finally, Wellington Management Group LLP grew its position in Kodiak Sciences by 304.7% in the fourth quarter. Wellington Management Group LLP now owns 473,796 shares of the company's stock valued at $13,247,000 after acquiring an additional 356,737 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

More Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Company reported advancing pipeline and strong Phase III data for Zenkuda that management highlighted alongside Q4/2025 results — this progress and accelerated regulatory planning support upside expectations for KOD. Kodiak Announces Q4 and FY2025 Results
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $58 price target even as it trimmed forecasts — that continued analyst endorsement can provide investor support and a clear upside reference point.
• Neutral Sentiment: Q4 results showed a wider-than-expected loss, but commentary focused investor attention on pipeline milestones rather than only near-term P&L metrics. Zacks: Q4 Loss Wider Than Expected
• Negative Sentiment: Multiple analysts (Lifesci Capital and HC Wainwright) cut near-term EPS estimates across Q1–Q4 2026 and lowered FY2026–FY2029/2030 forecasts — these downward revisions increase short-term earnings uncertainty and can pressure the stock. (Market commentary and analyst notes issued April 1)
• Negative Sentiment: Some cuts are large and extend into multi-year forecasts (HC Wainwright cut FY2026–FY2029/2030 estimates; Lifesci trimmed FY2026), signaling analysts see a longer recovery path to profitability — this raises risk for investors focused on near-term fundamentals.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.